Peiminine

Peiminine is a compound that can be isolated from Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae family). Peiminine can induce apoptosis in human hepatocellular carcinoma HepG2 cells through both extrinsic and intrinsic apoptotic pathways. Peiminine has anti-inflammatory, anticancer, anti-osteoporosis, cardioprotective and other activities in many animal models^{[1][2][3][4][5][6]}. In Vitro:Peiminine (2-6 μg/mL, 24 h) decreases the expressions of procaspase-3, procaspases-8 and -9 and increases the levels of caspase-3, 8, 9 protein in HepG2 cells^[1].
Peiminine (2-14 μg/mL, 24-72 h) displays the marked cytotoxicity to HepG2, Hela, SW480 and MCF-7 cells^[1].
Peiminine (2-6 μg/mL, 24 h) induces apoptosis in HepG2 cells^[1].
Peiminine (2-6 μg/mL, 24 h) induces HepG2 cells arrest at the G2/M phase^[1]. In Vivo:Peiminine (3mg/kg, intraperitoneal injection, single dose) alleviates inflammatory manifestations and mitigates intestinal tissue damage in an experimental model of ulcerative colitis^[2].
Peiminine (10 mg/kg, Intraperitoneal injection, once every 2 days for 6 weeks) prevents bone loss and fat formation in OVX-induced rat model^[3].
Peiminine (1-5 mg/kg, are applied to the dorsal skin, once daily for 16 days) inhibits serum IL-6 and TNF-α in the dinitrochlorobenzene (DNCB)-induced Allergic dermatitis animal model^[4].
Peiminine (2-5 mg/kg, Intraperitoneal injection, once a day for 4 weeks) has a cardioprotective effect against myocardial infarction-induced myocardial injury and fibrosis in myocardial infarction rat model^[5].
Peiminine (1-5 mg/kg, Intraperitoneal injection, single dose) can reduce the damage of inflammatory response to the body and the possibility of pulmonary edema in LPS-induced Acute lung injury model mice^[6].